Skip to main content
OpenTrials
Completed

NCT Number: NCT05121740

Extension Study in a Cohort of Adult Patients With COVID-19 Infection

The main objective of this study is to evaluate the incidence of post-COVID morbidity and characterize the complications profile in patients who participated in the APLICOV-PC study. APLICOV-PC study was a multicenter, randomized, proof-of-concept clinical trial to assess the safety profile of 3 different dose levels of plitidepsin (1,5 mg, 2,0 mg and 2,5 mg) administered three consecutive days, in adult patients with confirmed diagnosis of COVID-19 who require hospital admission.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain

Loading trial locations.

About this study

The APLICOV-PC proof of concept study demonstrated the antiviral activity of plitidepsin in terms of reducing viral load, inducing recovery, and impact on lymphocyte reconstitution and other inflammatory parameters.

A percentage of patients, which varies between 10 and 25%, continue to show symptoms at 3 months after contracting the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: For some of them this significantly restricts their life, requiring them to take long-term sickness leave from work, and leaving them with sequelae that may continue for more than one year.

With this study, Pharmamar intends to evaluate whether the treatment with plitidepsin, by attaining a reduction in the viral load and a faster recovery of the patient, could have a relevant impact on the emergence of sequelae resulting from the SARS-CoV-2 infection.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient who participated in the APLICOV-PC study receiving treatment with plitidepsin and who gives consent.

Exclusion criteria

  • There are no exclusion criteria for this study.

Treatment and study plan

Plitidepsin 1.5 mg / day

Drug

Plitidepsin 1.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 4.5 mg).

Plitidepsin 2.0 mg / day

Drug

Plitidepsin 2.0 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 6.0 mg).

Plitidepsin 2.5 mg / day

Drug

Plitidepsin 2.5 mg/day infused through a pump device over 1 hour and 30 minutes, 3 consecutive days (total dose 7.5 mg).

Primary outcomes

  1. Number and Percentage of Participants With Complications Related to Post COVID-19 Infection

    Time frame: Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months.

    Number and percentage of patients who developed complications related to post COVID-19 infection

Secondary outcomes

  1. Patients Requiring Oxygen Therapy

    Time frame: Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months.

    Percentage of patients requiring oxygen therapy

  2. Patients With Complications Post COVID-19 Infection (Regardless Relationship, i.e. Related to COVID-19 Infection or Not).

    Time frame: Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months..

    Percentage of patients with complications Post COVID-19 Infection (Regardless Relationship, i.e. Related to COVID-19 Infection or Not).

  3. Ratio of Partial Pressure Arterial Oxygen (PaO2) and Fraction of Inspired Oxygen (FiO2)

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    PaO2/FiO2 (Ratio of partial pressure arterial oxygen and fraction of inspired oxygen) mean, standard deviation.

    PaO2/FiO2 ratio to evaluate disease severity and discriminate between 'Moderate' and 'Severe' categories according to FDA guidance.

  4. Forced Expiratory Volume 1 (FEV1)

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    FEV1 (Forced expiratory volume 1) mean, standard deviation.

  5. Lung Diffusion Testing

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    Lung difussion testing: mean and standard deviation. Unit of measure: % reference theoretical value

  6. Patients With Alterations in Chest Radiography

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    Percentage of patients with alterations in chest radiography

  7. Patients With Electrocardiogram Alterations

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    Percentage of patients with electrocardiogram alterations

  8. Patients With ≥Grade 2 Alterations in Laboratory Parameters

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    Percentage of patients with ≥grade 2 alterations in laboratory parameters Grade measured according to NCI-CTCAE v5.0 (National Cancer Institute - Common Terminology Criteria for Adverse Events version 5.0) where Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.

    Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL* Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.

  9. Modified Medical Research Council (mMRC) Dyspnea Scale

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    Percentage of patients in each category of the Modified Medical Research Council (mMRC) dyspnea scale.

    The mMRC scale is a self-rating tool to measure the degree of disability that breathlessness poses on day-to-day activities on a scale from 0 to 4:

    0, no breathlessness except on strenuous exercise;

    • shortness of breath when hurrying on the level or walking up a slight hill;
    • walks slower than people of same age on the level because of breathlessness or has to stop to catch breath when walking at their own pace on the level;
    • stops for breath after walking ∼100 m or after few minutes on the level; and
    • too breathless to leave the house, or breathless when dressing or undressing.
  10. FEV1/FVC

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    FEV1/FVC mean, standard deviation.

  11. Forced Vital Capacity (FVC)

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    FVC mean, standard deviation.

  12. Arterial Oxygen Saturation (SaO2)

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    SaO2 (Arterial oxygen saturation) mean, standard deviation. Unit of measure: percentage of oxygen saturation

  13. Barthel Index

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    The Barthel index measures the extent to which somebody can function independently and has mobility in their activities of daily living (ADL) i.e. feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation and stair climbing.

    Percentage of patients at each category according to the score obtained: 0-20: Total dependence; 21-60: Severe dependence; 61-90: Moderate dependence; 91-99: Low dependence; 100: Independence

  14. Patients Requiring Hospital Readmission

    Time frame: Since last visit of APLICOV-PC study until the end of this extension study, an average of 12 months.

    Percentage of patients requiring hospital readmission

  15. 6 Minute Walking Test (Total Distance)

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    minute walking test mean, standard deviation. Total distance measured in meters (m)

  16. 6 Minute Walking Test (Expected Distance)

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    minute walking test mean, standard deviation. Expected distance (the predicted distance that a patient could walk) measured in meters (m)

  17. 6 Minute Walking Test (Percentage of Predicted Distance)

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    6 minute walking test mean, standard deviation. Unit of measure: Percentage of predicted distance

  18. 6 Minute Walking Test (Number of Laps of 60 m)

    Time frame: At study inclusion, an average of 12 months after end of APLICOV-PC study.

    6 minute walking test mean, standard deviation. Unit of measure: Number of laps of 60 m

Sponsors and collaborators

Lead sponsor

PharmaMar

Industry

Collaborators

  • Apices Soluciones S.L.

Registry information

Official study title

Extension Study in a Cohort of Adult Patients With SARS-CoV-2 Infection Requiring Hospital Admission and Received Treatment With Plitidepsin in the APLICOV-PC Study

Acronym: E-APLICOV-PC

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Nov 16, 2021
Registry last updated
Dec 31, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.